Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.54 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13551805 | 0.90 | CARM1 (0.52) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL19773049 | 0.86 | CCR3 (0.56) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL13537190 | 0.85 | CCR3 (0.54) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL23022734 | 0.84 | CARM1 (0.57) | CARM1PRMT6 | |
| SCHEMBL20314564 | 0.83 | SIGMAR1 (0.43) | CCR3KCNH2 | |
| SCHEMBL16219450 | 0.83 | CYP19A1 (0.45) | CCR3ALDH1A1 | |
| SCHEMBL13622087 | 0.83 | MEN1 (0.48) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL23022794 | 0.83 | GRIN2B (0.46) | GRIN2B | |
| SCHEMBL13551807 | 0.81 | CCR3 (0.44) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL23022733 | 0.81 | MAOA (0.47) | GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | EMORY UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | RORA, RORB, RORC | CCR3 758/4885CARM1 475/4885PRMT6 1909/4885 |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | CCR3 4336/4885CARM1 2100/4885PRMT6 2263/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | CCR3 4336/4885CARM1 2100/4885PRMT6 2263/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | CCR3 197/4885CARM1 2128/4885PRMT6 3081/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | CCR3 4490/4885CARM1 1657/4885PRMT6 2039/4885 |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | CCR3 4219/4885CARM1 393/4885PRMT6 239/4885 |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | HGF, IL2, IL2RA | CCR3 86/4885CARM1 1160/4885PRMT6 614/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CCR3 1353/4885CARM1 2862/4885PRMT6 3447/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | CCR3 4418/4885CARM1 3156/4885PRMT6 2826/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | CCR3 3565/4885CARM1 4286/4885PRMT6 1222/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | CCR3 4219/4885CARM1 393/4885PRMT6 239/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | CCR3 1301/4885CARM1 3010/4885PRMT6 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.